Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR-Reference-Cited by-同舟云学术

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

Published:2012-01-26 Issue:7387 Volume:483 Page:100-103
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Prahallad Anirudh,Sun Chong,Huang Sidong,Di Nicolantonio Federica,Salazar Ramon,Zecchin Davide,Beijersbergen Roderick L.,Bardelli Alberto,Bernards René

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature10868.pdf

Reference22 articles.

1. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011)

2. Roth, A. D. et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J. Clin. Oncol. 28, 466–474 (2010)

3. Richman, S. D. et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J. Clin. Oncol. 27, 5931–5937 (2009)

4. Kopetz, S. et al. PLX4032 in metastatic colon cancer patients with mutant BRAF tumors. J. Clin. Oncol. 28 abstract 3534 (2010)

5. Tol, J., Nagtegaal, I. D. & Punt, C. J. BRAF mutation in metastatic colorectal cancer. N. Engl. J. Med. 361, 98–99 (2009)

Cited by 1720 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of mitochondria and potential of mitochondria-targeted therapy in BRAF mutant cancer: A review;Critical Reviews in Oncology/Hematology;2024-11

2. Transcriptomic subtyping of gastrointestinal malignancies;Trends in Cancer;2024-09

3. BRAF-Mutant Metastatic Colorectal Cancer: Current Evidence, Future Directions, and Research Priorities;Clinical Colorectal Cancer;2024-09

4. Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study;ESMO Open;2024-09

5. Colorectal Cancer with BRAF V600E Mutation: Trends in Immune Checkpoint Inhibitor Treatment;Critical Reviews in Oncology/Hematology;2024-09